AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3802956
Drug: High-dose recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose recombinant interferon-alpha-2a (18 X 10(6) U daily for one week)
Trial: 3802956
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group switched to high-dose (18 X 10(6) U daily for another 7 days)
Trial: 3802956
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group switched to low-dose (3 X 10(6) U daily for another 7 days)
Trial: 31870450
Drug: Patchouli alcohol
RxNorm normalized name: oil of patchouli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patchouli alcohol (PA) administered intranasally
Trial: 23187648
Drug: Losartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan treatment in patients with HFrEF
Trial: 10523477
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 30 mg/day
Trial: 10523477
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 60 mg/day
Trial: 10523477
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 90 mg/day
Trial: 10523477
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS mean dose of 52.3 mg/day during one-year open label phase
Trial: 8748432
Drug: CI-988 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-988 (300 mg/day, thrice daily)
Trial: 3885441
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia with paracetamol 320 mg, caffeine 32 mg, codeine phosphate 8 mg, and meprobamate 150 mg (Stopayne)
Trial: 3885441
Drug: Oral analgesia
RxNorm normalized name: P-A-C Analgesic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral analgesia with dipyrone 500 mg, pitofenone hydrochloride 5 mg, and fenpiverinium bromide 0.1 mg (Baralgan HS)
Trial: 3885441
Drug: Parenteral administration
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of pethidine 100 mg
Trial: 3885441
Drug: Parenteral administration
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of dipyrone 2500 mg
Trial: 31887803
Drug: Hyaluronidase injection
RxNorm normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase injection (5000 IU)
Trial: 27591953
Drug: Low-dose vaccine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vaccine (7.5 mcg HA)
Trial: 27591953
Drug: High-dose vaccine
RxNorm normalized name: Fluzone 2023-2024 high-dose vaccine Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vaccine (15 mcg HA)
Trial: 24289244
Drug: 1064-nm Q-switched
RxNorm normalized name: Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064-nm Q-switched Nd:YAG laser plus chemical peeling with Jessner's solution
Trial: 16096831
Drug: Darifenacin 15
RxNorm normalized name: darifenacin 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 15 mg once daily (q.d.)
Trial: 16096831
Drug: Darifenacin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darifenacin 30 mg once daily (q.d.)
Trial: 16096831
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg three times daily (t.i.d.)
Trial: 10603716
Drug: Immunohistochemical detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical detection using LAM antibody
Trial: 10603716
Drug: Immunohistochemical detection
RxNorm normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunohistochemical detection using PGL-1, 30 kD and 65 kD antibodies
Trial: 2041036
Drug: felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: felodipine 5 mg ER formulation
Trial: 6992910
Drug: Naftidrofuryl (Praxilene)
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (Praxilene) 200 mg t.d.s. for 6 months
Trial: 26107684
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium Carbonate Chewable D3 tablet (thrice daily)
Trial: 26107684
Drug: MESE exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MESE exercise (thrice daily, 7 repetitions per time for 12 months)
Trial: 26107684
Drug: MESE exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MESE exercise + Calcium Carbonate Chewable D3 tablet (thrice daily for 12 months)
Trial: 26107684
Drug: MESE exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MESE exercise + Calcium Carbonate Chewable D3 tablet
Trial: 21040197
Drug: LFD fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LFD fluconazole prophylaxis (twice a week for up to 6 weeks)
Trial: 17466699
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered 15-60 minutes prior to skin incision
Trial: 17466699
Drug: Cefazolin administered
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin administered at the time of cord clamping
Trial: 15478524
Drug: Midodrine 5
RxNorm normalized name: midodrine 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine 5 mg
Trial: 10021952
Drug: Epidural F
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural F (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 saline followed by 2 micrograms.ml‐1 fentanyl infusion)
Trial: 10021952
Drug: Epidural F‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural F‐B (fentanyl bolus 2 micrograms.kg‐1 in 0.5 ml.kg‐1 bupivacaine 0.25% followed by 2 micrograms.ml‐1 fentanyl infusion in bupivacaine 0.125%)
Trial: 25430779
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg GSK561679 (low-GSK)
Trial: 25430779
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg GSK561679 (high-GSK)
Trial: 20089518
Drug: Functional MBL
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional MBL deficiency (serum MBL levels of or below 100 ng/mL)
Trial: 20089518
Drug: MBL levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBL levels >100 ng/mL
Trial: 14639800
Drug: DHA-enriched eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched eggs (147 mg DHA/egg)
Trial: 14639800
Drug: Ordinary eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary eggs (20 mg DHA/egg)
Trial: 14639800
Drug: DHA-enriched eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-enriched eggs (147 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Trial: 14639800
Drug: Ordinary eggs
RxNorm normalized name: EGG
DrugBank: Egg (DB10529)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary eggs (20 mg DHA/egg) in subjects with BMI >= 30 kg/m2
Trial: 10868315
Drug: Ropinirole (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.5 mg bid, titrated to a maximum of 6.0 mg tid)
Trial: 10868315
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-dopa and ropinirole
Trial: 8989068
Drug: Sparfloxacin (Spfx),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (Spfx), 400 mg on day 1, then 200 mg once daily for 10 to 14 days
Trial: 8989068
Drug: Roxithromycin (ROXI),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin (ROXI), 150 mg twice daily for 10 to 14 days
Trial: 1456812
Drug: Aclarubicin in
RxNorm normalized name: aclarubicin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin in combination with cytarabine (7 + 7)
Trial: 1456812
Drug: Aclarubicin in
RxNorm normalized name: aclarubicin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin in combination with cytarabine (5 + 5)
Trial: 1456812
Drug: Aclarubicin in
RxNorm normalized name: aclarubicin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin in combination with cytarabine (7 & 3)
Trial: 1456812
Drug: Aclarubicin in
RxNorm normalized name: aclarubicin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aclarubicin in combination with cytarabine (7 + 3)
Trial: 31698825
Drug: Pemafibrate 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.4 mg/day
Trial: 31698825
Drug: Pemafibrate (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate (all doses)
Trial: 29379953
Drug: Extended intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended intervention (medication review, 3 motivational interviews, follow-up with primary care physician, pharmacy, and nursing home)
Trial: 29379953
Drug: Basic intervention
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic intervention (medication review)
Trial: 22328287
Drug: HAIC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC plus systemic chemotherapy (combined therapy)
Trial: 22328287
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy alone (monotherapy)
Trial: 20123413
Drug: Buccal-plus-lingual infiltrations
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal-plus-lingual infiltrations
Trial: 10707439
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months) + Nicotine inhalers (6-12 units/day for up to 6 months)
Trial: 10707439
Drug: Nicotine inhalers
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine inhalers (6-12 units/day for up to 6 months) + Placebo (10 mg daily for 16 days, then 20 mg for 10 days, continuing for at least 3 months)
Trial: 1763608
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium followed by daily oral magnesium tablets
Trial: 1763608
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion followed by daily oral placebo tablets
Trial: 29304744
Drug: High carotenoid
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High carotenoid diet (375 g/d high carotenoid vegetables, 300 g/d high carotenoid fruit, 40-60 ml extra-virgin olive oil)
Trial: 29304744
Drug: Lower carotenoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower carotenoid diet (375 g/d lower carotenoid vegetables, 300 g/d lower carotenoid fruit, 40-60 ml PUFA based oil)
Trial: 27135207
Drug: Adjunctive couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive couples intervention (n=19)
Trial: 17986161
Drug: Tramadol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol added to transdermal fentanyl (group T)
Trial: 17986161
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl alone (group F)
Trial: 24878686
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted smoking cessation intervention (8 weekly 40-min counseling sessions with Korean-specific cultural elements)
Trial: 24878686
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation intervention (8 weekly 10-min counseling sessions not culturally adapted)
Trial: 23134470
Drug: Daily everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily everolimus (7.5 mg)
Trial: 23134470
Drug: Weekly everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly everolimus (70 mg)
Trial: 23134470
Drug: Daily everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily everolimus (7.5 mg) in HBsAg‐seropositive patients
Trial: 23134470
Drug: Weekly everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly everolimus (70 mg) in HBsAg‐seropositive patients
Trial: 15199081
Drug: Oxymorphone ER
RxNorm normalized name: oxymorphone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone ER 20 mg q12h for 1 day
Trial: 12815774
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (7.5% - 1 ml/kg b.w.)
Trial: 11593959
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral treatment
Trial: 2952435
Drug: Random blood
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random blood glucose measurement (thresholds: 6.1 mmol/l within 2 h of eating, 5.6 mmol/l at greater than 2 h of food)
Trial: 2952435
Drug: Formal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formal oral glucose tolerance test
Trial: 28767209
Drug: Suvorexant (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suvorexant (15 mg/d)
Trial: 9268234
Drug: Simvastatin 5
RxNorm normalized name: simvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 5 mg/day
Trial: 8337639
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia with intravenous sedation
Trial: 26490353
Drug: Fostamatinib 50-200
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 50-200 mg (single and multiple dosing)
Trial: 26490353
Drug: Fostamatinib 150
RxNorm normalized name: fostamatinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 150 mg (single dose)
Trial: 26490353
Drug: Fostamatinib 100
RxNorm normalized name: fostamatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib 100 and 200 mg (open-label study)
Trial: 26490353
Drug: Fostamatinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib (all doses)
Trial: 26490353
Drug: Fostamatinib 200
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib 200 mg
Trial: 11446908
Drug: Amoxicillin-sulbactam 875/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-sulbactam 875/125 mg
Trial: 11446908
Drug: Sulbactam 125
RxNorm normalized name: sulbactam 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactam 125 mg
Trial: 9506730
Drug: G+T (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+T (three large gin with regular tonics, 0.5 g/kg alcohol and 60 g carbohydrate)
Trial: 9506730
Drug: G alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G alone (same amount of alcohol with Slim‐line tonic, 0.5 g carbohydrate)
Trial: 9506730
Drug: G+T
RxNorm normalized name: Gentamicin + Tobramycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G+T
Trial: 7890893
Drug: alpha‐2a interferon,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐2a interferon, 1 megaunit thrice weekly for 6 months
Trial: 7890893
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no maintenance treatment)
Trial: 3126012
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (NTG) 10 mg/24 h
Trial: 27337519
Drug: Tribulus terrestris
RxNorm normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tribulus terrestris (750 mg in three divided doses for three months)
Trial: 25977745
Drug: Budesonide inhalation
RxNorm normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide inhalation suspension (BIS) 0.5 mg three times a day
Trial: 25977745
Drug: Methylprednisolone (mPSL)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (mPSL) 1 mg/kg three times a day
Trial: 21972156
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of nitroglycerin plus 2.5 mg of verapamil (Group 1)
Trial: 21972156
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of verapamil alone (Group 2)
Trial: 18775652
Drug: Cortisol and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol and dexamethasone treatment under basal conditions in responders
Trial: 18775652
Drug: Cortisol and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol and dexamethasone treatment after stimulation with phytohemagglutinin in responders
Trial: 18775652
Drug: Cortisol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol treatment in responders
Trial: 18775652
Drug: Cortisol and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol and dexamethasone treatment in responders
Trial: 12712826
Drug: Cefoperazone 2
RxNorm normalized name: cefoperazone 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone 2 x 1.0 g i.v. daily (group I = 20 persons)
Trial: 12712826
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 x 0.5 g (group II = 20 persons)
Trial: 9103292
Drug: 25,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25,000 IU retinol daily for 5 years
Trial: 9103292
Drug: 5-10 mg
RxNorm normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-10 mg isotretinoin daily for 3 years
Trial: 8397560
Drug: Moderate-fiber dose
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate-fiber dose (40 to 60 gm)
Trial: 8397560
Drug: High-fiber dose
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber dose (70 to 80 gm)
Trial: 22182258
Drug: Probiotic chewing
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic chewing gum containing L. reuteri DSM 17938 and L. reuteri ATCC PTA 5289
Trial: 16643581
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg haloperidol in 500 mL of normal saline
Trial: 16643581
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of normal saline (placebo)
Trial: 16643581
Drug: Relapse after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relapse after treatment
Trial: 12826040
Drug: Intravenous ZD9331
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ZD9331 (n=30), on days 1 and 8 of a 3‐week cycle
Trial: 12826040
Drug: Intravenous gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gemcitabine (n=25), once a week for 7 weeks followed by a 1‐week rest, then on days 1, 8 and 15 of a 4‐week cycle
Trial: 31331907
Drug: Exubera (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exubera (insulin human [rDNA origin], inhaled powder)
Trial: 31331907
Drug: Other diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other diabetes treatments (control)
Trial: 21227540
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous metoclopramide